NKGen Biotech, Inc.

NKGen Biotech, Inc. filed an 8-K on September 18, 2023, reporting the closing of its business combination with Graf Acquisition Corp. IV, which had traded on Nasdaq under the ticker GFOR. Graf Acquisition Corp. IV was sponsored by Graf Acquisition Holdings IV LLC, an affiliate of Graf Industrial Corp., and completed its IPO in 2021 targeting the healthcare and biotechnology sector. NKGen Biotech is a clinical-stage biopharmaceutical company focused on natural killer cell therapy, with its lead programs aimed at neurodegenerative diseases and oncology indications. Upon closing of the transaction, the combined company began trading under the ticker NKGN. Visit SpacDesk and sign up for full data, filings, and deal history on this and every other SPAC transaction.